The AMD Experts
We’re on a mission to eliminate blindness caused by age-related macular degeneration (AMD). Our vision is bold but well within reach.
MacuLogix® is the only company to equip eye care professionals with the technology, tools and education needed to identify and manage AMD patients early, before irreversible vision loss has occurred. We can help you deliver better patient care with the scientifically-validated, FDA 510(k)-cleared AdaptDx®.
Help us save the eyesight of millions by making early functional testing for AMD a routine part of eye care for your aging patients.
The MacuLogix team is committed to empowering primary eye care professionals with the technology and tools needed to create AMD Centers of Excellence.
Bill McPhee, the President and CEO of MacuLogix, shares his personal story of why he joined the company and adopted its vision of eliminating blindness caused by AMD.
Latest News & Upcoming EventsView More
Laurie Sorrenson, OD, discusses early AMD treatment in Primary Care Optometry News.
AdaptDx® has been selected as a functional testing device in the MACUSTAR project, a 5-year study to explore AMD.
How preventive care is changing the European landscape when tackling AMD. By Armond Dantino
The AdaptDx is especially useful for optometrists and general ophthalmologists who see many patients with “normal” clinical exams, since it can detect subclinical AMD up to three years before clinical onset. With the AdaptDx, you will be in the front line in detecting these patients and will be able to carefully monitor and treat those with subclinical AMD.